IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Bought by Sheaff Brock Investment Advisors LLC

Sheaff Brock Investment Advisors LLC lifted its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 6.1% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 2,985 shares of the company’s stock after purchasing an additional 172 shares during the quarter. Sheaff Brock Investment Advisors LLC’s holdings in IDEXX Laboratories were worth $1,508,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Vanguard Group Inc. grew its stake in shares of IDEXX Laboratories by 1.2% during the 1st quarter. Vanguard Group Inc. now owns 8,476,054 shares of the company’s stock worth $4,576,476,000 after purchasing an additional 98,387 shares during the period. American Century Companies Inc. grew its stake in shares of IDEXX Laboratories by 46.0% during the 2nd quarter. American Century Companies Inc. now owns 562,764 shares of the company’s stock worth $274,179,000 after purchasing an additional 177,226 shares during the period. International Assets Investment Management LLC grew its stake in shares of IDEXX Laboratories by 52,746.0% during the 3rd quarter. International Assets Investment Management LLC now owns 528,460 shares of the company’s stock worth $2,669,890,000 after purchasing an additional 527,460 shares during the period. Dimensional Fund Advisors LP grew its stake in IDEXX Laboratories by 13.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 512,788 shares of the company’s stock valued at $249,855,000 after acquiring an additional 59,519 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA grew its stake in IDEXX Laboratories by 12.5% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 390,565 shares of the company’s stock valued at $190,283,000 after acquiring an additional 43,473 shares during the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

IDXX has been the topic of a number of research reports. Piper Sandler reissued a “neutral” rating and issued a $435.00 price objective (down from $520.00) on shares of IDEXX Laboratories in a research note on Monday, November 4th. BTIG Research initiated coverage on shares of IDEXX Laboratories in a research note on Thursday, July 25th. They issued a “buy” rating and a $580.00 price objective on the stock. JPMorgan Chase & Co. lowered their price objective on shares of IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating on the stock in a research note on Friday, October 11th. Stifel Nicolaus lowered their price objective on shares of IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating on the stock in a research note on Thursday, October 10th. Finally, Barclays reduced their target price on shares of IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating on the stock in a report on Monday, November 4th. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $552.38.

IDEXX Laboratories Trading Down 1.4 %

Shares of IDXX stock opened at $423.65 on Friday. The firm has a market cap of $34.69 billion, a P/E ratio of 40.85, a PEG ratio of 3.75 and a beta of 1.36. IDEXX Laboratories, Inc. has a 1-year low of $404.74 and a 1-year high of $583.39. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.42 and a quick ratio of 1.03. The firm’s 50-day simple moving average is $470.26 and its 200-day simple moving average is $483.80.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Thursday, October 31st. The company reported $2.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.69 by $0.11. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. The company had revenue of $975.50 million during the quarter, compared to the consensus estimate of $980.32 million. During the same quarter last year, the company earned $2.53 earnings per share. IDEXX Laboratories’s revenue for the quarter was up 6.6% on a year-over-year basis. As a group, equities analysts forecast that IDEXX Laboratories, Inc. will post 10.43 EPS for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.